Track 05 of 9
Metabolic Syndrome
Insulin resistance, NAFLD and cardiometabolic risk.
Cardiovascular-Kidney-Metabolic (CKM) syndrome, formalized by the AHA in 2023, reframes obesity, insulin resistance, MASLD, CKD, and ASCVD as a single pathophysiologic continuum. The track will cover resmetirom (Rezdiffra), the first FDA-approved MASH therapy, alongside GLP-1 and GGG agonist data in steatohepatitis (ESSENCE, SYNERGY-NASH). Sessions will address sarcopenic obesity and lean-mass preservation during rapid weight loss, the epidemiology of obesity-driven HFpEF, obstructive sleep apnea response to tirzepatide (SURMOUNT-OSA), and the integration of CKM staging into primary-care risk assessment.
Focus areas
- AHA CKM syndrome staging and primary-care implementation
- Resmetirom and the MASH pharmacotherapy pipeline
- GLP-1 and GGG agonists in MASLD/MASH (ESSENCE, SYNERGY-NASH)
- Sarcopenic obesity: lean-mass preservation during weight loss
- SURMOUNT-OSA: tirzepatide for obstructive sleep apnea
- Obesity-driven HFpEF and incretin-based therapy
- Insulin resistance, ectopic fat and visceral adiposity imaging